Teacher Retirement System of Texas Buys 950,358 Shares of Pfizer Inc. (NYSE:PFE)

Teacher Retirement System of Texas increased its holdings in shares of Pfizer Inc. (NYSE:PFE - Free Report) by 93.3% during the 4th quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 1,969,261 shares of the biopharmaceutical company's stock after acquiring an additional 950,358 shares during the period. Teacher Retirement System of Texas' holdings in Pfizer were worth $52,244,000 at the end of the most recent reporting period.

A number of other hedge funds have also modified their holdings of PFE. Retirement Wealth Solutions LLC acquired a new stake in shares of Pfizer in the 4th quarter valued at approximately $26,000. Rialto Wealth Management LLC acquired a new position in Pfizer during the 4th quarter worth approximately $26,000. Kohmann Bosshard Financial Services LLC bought a new position in Pfizer in the fourth quarter valued at $28,000. Noble Wealth Management PBC acquired a new stake in shares of Pfizer in the fourth quarter valued at about $31,000. Finally, Curio Wealth LLC bought a new stake in shares of Pfizer during the 4th quarter worth approximately $32,000. 68.36% of the stock is owned by institutional investors and hedge funds.

Insider Buying and Selling at Pfizer

In other Pfizer news, Director Ronald E. Blaylock purchased 19,457 shares of the company's stock in a transaction dated Thursday, February 13th. The shares were acquired at an average price of $25.65 per share, for a total transaction of $499,072.05. Following the purchase, the director now directly owns 27,707 shares of the company's stock, valued at $710,684.55. The trade was a 235.84 % increase in their position. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. Corporate insiders own 0.06% of the company's stock.

Remove Ads

Analyst Ratings Changes

PFE has been the topic of a number of recent research reports. UBS Group lowered their target price on Pfizer from $31.00 to $29.00 and set a "neutral" rating on the stock in a research note on Wednesday, January 8th. Guggenheim reissued a "buy" rating on shares of Pfizer in a research note on Tuesday, March 18th. Hsbc Global Res raised Pfizer to a "strong-buy" rating in a research note on Monday, March 10th. Citigroup decreased their price objective on Pfizer from $30.00 to $29.00 and set a "neutral" rating for the company in a report on Tuesday, January 28th. Finally, Bank of America restated a "neutral" rating and issued a $29.00 price target on shares of Pfizer in a research report on Tuesday, December 10th. One research analyst has rated the stock with a sell rating, seven have assigned a hold rating, six have assigned a buy rating and three have issued a strong buy rating to the company's stock. According to MarketBeat, the stock has an average rating of "Moderate Buy" and a consensus target price of $31.92.

Pfizer Stock Performance

Shares of PFE traded down $0.15 during mid-day trading on Monday, hitting $26.13. 37,863,216 shares of the company traded hands, compared to its average volume of 36,651,008. Pfizer Inc. has a 1 year low of $24.48 and a 1 year high of $31.54. The company has a debt-to-equity ratio of 0.63, a quick ratio of 0.73 and a current ratio of 1.00. The stock has a 50-day moving average price of $26.17 and a two-hundred day moving average price of $27.04. The stock has a market cap of $148.21 billion, a price-to-earnings ratio of 18.53, a P/E/G ratio of 0.64 and a beta of 0.61.

Pfizer (NYSE:PFE - Get Free Report) last released its quarterly earnings results on Tuesday, February 4th. The biopharmaceutical company reported $0.63 earnings per share for the quarter, beating the consensus estimate of $0.48 by $0.15. Pfizer had a return on equity of 19.47% and a net margin of 12.62%. The firm had revenue of $17.76 billion for the quarter, compared to analysts' expectations of $17.26 billion. During the same period in the prior year, the firm earned $0.10 EPS. The company's revenue was up 24.7% compared to the same quarter last year. Equities analysts anticipate that Pfizer Inc. will post 2.95 earnings per share for the current year.

Pfizer Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.